FDA approves Alzheimer’s drug that slowed cognitive decline in clinical trial
The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment
Read moreThe FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment
Read moreThese are the stocks posting the largest moves in midday trading. Source link
Read moreNames on the move ahead of the open. Source link
Read moreIt's the last day of November, and the Dow and S&P 500 are poised to log their second straight month
Read moreNames on the move ahead of the open. Source link
Read moreFollowing our price target changes on eight Club holdings last month, we're updating three more Tuesday. Source link
Read moreInvestors are likely to switch their focus to earnings season, after the market's wild ride on rising and falling expectations
Read moreBiogen's Chief Executive Officer Michel Vounatsos is stepping down as it is grappling with Medicare restricting coverage for its Alzheimer's
Read moreHere are the biggest calls on Wall Street on Source link
Read more